August 27th, 2021 | 11:53 CEST
BioNTech, XPhyto, Moderna - Boosters for the portfolio
Globally, infection numbers are rising dramatically due to the highly contagious Delta variant. According to the RKI, 12,626 new infections were reported in Germany alone, 4,226 more than a week ago. With the incidence rising above the authoritative level of 35, greater emphasis is again being placed on the rule, vaccinated, recovered or tested. As a result, demand for PCR or rapid tests is skyrocketing. Diagnostic companies, like vaccine producers, are in for a warm cash shower.
time to read: 3 minutes
|
Author:
Stefan Feulner
ISIN:
BIONTECH SE SPON. ADRS 1 | US09075V1026 , XPHYTO THERAPEUTICS | CA98421R1055 , MODERNA INC. DL-_0001 | US60770K1079
Table of contents:
"[...] Defence will continue to develop its Antibody Drug Conjugates "ADC" and its radiopharmaceuticals programs, which are currently two of the hottest products in demand in the pharma industries where significant consolidations and take-overs occurred. [...]" Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.
Author
Stefan Feulner
The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.
Tag cloud
Shares cloud
XPhyto - On many feet
Whether it is a restaurant, movie theater or gym, once the incidence of 35 has been exceeded, only those vaccinated, tested, or recovered are allowed in. Currently, around 60% or just under 50 million people in Germany are fully vaccinated. Thus, the need for PCR or rapid tests continues to exist and is expected to increase tremendously as the numbers rise. With the Covid-ID Lab, the bioscience incubator XPhyto is preparing to get a bigger piece of the USD 40 billion rapid test market. In cooperation with Stuttgart-based 3a-diagnostics GmbH, for which XPhyto has an option to purchase for a price of just under EUR 4 million, a universally applicable PCR test has been developed.
The test was already approved in the second quarter. The advantage of the COVID-19 RT-PCR test system "Covid-ID Lab" is that results are delivered after only 20 to 25 minutes, as prior RNA extraction is not required as part of sample preparation. The product thus lies between disposable antigen tests and centralized, automated PCR systems and is to be used preferably at airports, pharmacies and medical care facilities.
In addition to the Covid-ID Lab, the focus is on investing in next-generation drug delivery, diagnostics and new active pharmaceutical ingredients. Acquisition target 3a-diagnostics recently identified the first saliva-activated biosensor candidates to detect COVID-19 infection in the mouth, marking another milestone. The enzyme-activated biosensors are being developed to provide cost-effective and straightforward oral screening tests for direct and rapid detection of infectious diseases, including COVID-19, at home or the point of care. XPhyto intends to continue to grow both organically and through targeted acquisitions. The stock already holds long-term potential due to its broad range of innovations.
BioNTech - Shortly before approval
The share prices of vaccine manufacturers such as BioNTech and Moderna have gone through the roof in recent months. Driven by largely positive news, the Mainz-based companies reached a stock market value of over EUR 75 billion at their recent highs. They were twice as expensive in terms of market capitalization as the pharmaceutical and agricultural giant Bayer. Nevertheless, the momentum speaks for a further test of the all-time highs at USD 463.93. Only a fall below the level of USD 325 would color the chart picture negatively. Invested investors should therefore tighten their stop price upwards.
On the news front, BioNTech can continue to shine. Thus, in cooperation with the US partner Pfizer, further data for the approval of a booster vaccination against the coronavirus are to be submitted to the US Food and Drug Administration (FDA). A Phase 3 study showed that the booster vaccination with the vaccine had "significant neutralizing antibody titers" against the virus. "Neutralizing Sars-CoV-2 titers against the wild-type strain one month after the booster dose were 3.3 times higher than titers after the conventional second dose of vaccine," the statement said.
Moderna - Recall from Japan
Even more explosive than BioNTech's valuation was that of its US counterpart, Moderna. At EUR 129.11 billion, this makes the Company more valuable than pharmaceutical giants Amgen or Merck. Currently, the stock market price is USD 397 billion, clearly too high for Bank of America analysts. According to expert Geoff Meacham, the valuation cannot be justified based on the fundamental data. Therefore, the verdict is "Underperform," with a price target of USD 115.
Bad news also came from Japan. Here, 1.6 million doses of the vaccine were withdrawn due to impurities. It is purely a precautionary measure, and there are no concerns regarding efficacy and safety. The reason is reports of contamination in some ampoules.
The fourth wave is rolling towards Germany, and the demand for corona testing is skyrocketing. XPhyto is a promising player in the diagnostics market here. Although vaccine manufacturers continue to be imaginative, valuations are too high.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.
The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.
